Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

9.480 +0.630 (+7.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129,969
Open 8.740
Bid (Size) 8.880 (1)
Ask (Size) 9.510 (1)
Prev. Close 8.850
Today's Range 8.510 - 9.500
52wk Range 6.110 - 19.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Discover the top movers in Monday's pre-market session.
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill

Performance

YTD
-21.0%
-21.0%
1 Month
+30.9%
+30.9%
3 Month
-25.6%
-25.6%
6 Month
-37.1%
-37.1%
1 Year
-39.6%
-39.6%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024
Via InvestorPlace
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
From Gyre Therapeutics Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
From Gyre Therapeutics Inc.
Via GlobeNewswire
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
From Gyre Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Gyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gyre Therapeutics, Inc. - Common Stock trade on?
Gyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Gyre Therapeutics, Inc. - Common Stock is GYRE on the Nasdaq Stock Market
What is the current price of Gyre Therapeutics, Inc. - Common Stock?
The current price of Gyre Therapeutics, Inc. - Common Stock is 9.480
When was Gyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Gyre Therapeutics, Inc. - Common Stock was at 05/08/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.